August 30, 2022 — Abbott announced new late-breaking data that show its HeartMate 3 heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease.

August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fracti

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial.

August 29, 2022 — Amarin Corporation plc announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. 

August 29, 2022 — In a first-of-its-kind randomized clinical trial led by researchers at the 

August 29, 2022 — ­The US Preventive Services Task Force (USPSTF) has issued a Recommendation Statement, relating to Statin Use for the Primary Prevention of Cardiovascular Disease in Adults, published in the Journal of American Medical Association (JAMA), August 23, 2022.

August 26, 2022 — COVID mRNA vaccines are associated with a decreased risk of death in patients with heart failure, according to research presented at ESC Congress 2022. The study also found that the vaccines were not associated

August 26, 2022 — Researchers in the Smidt Heart Institute at Cedars-Sinai are one step closer to identifying patients at highest risk for developing sudden cardiac death—an electrical malfunction in the heart that causes it to stop beating. 

August 26, 2022 — The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program is now available for the TCT MedTech Innovation Forum.

August 25, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron Emission Tomography (PET) Imaging Assessment of Myocardial Perfusion in Patients Referred for Invasive Angiography Because of Suspected Coronary Artery Disease (CAD)” will be presented for the first time at 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now